Zelluna ASA - Remuneration Information 2023

Ultimovacs ASA - Share Option Program

Oslo, 21 April 2023: On the basis of the approval by the General Meeting on 20

April 2023 to authorize the Board of Directors of Ultimovacs ASA (the 'Company',

OSE ticker "ULTI") to issue new shares to employees under a long-term incentive

program, the Board of Directors has resolved to issue share options to employees

in the Company.

A total of 160,000 options for shares in the Company have been distributed

amongst the employees. The number of options granted corresponds to 0.47% of the

outstanding number of shares in the Company. Each option gives the right to

acquire one share in the Company. The options are granted without consideration.

Pursuant to the vesting schedule, 25% of the options will vest one year after

the day of grant, 25% of the options will vest two years after the day of grant

and the remaining 50% will vest three years after the day of grant (vesting is

dependent on the option holder still being employed in the Company).

The exercise price for the options granted is NOK 128.61 per share.

Options that are not exercised within 7 years from the date of grant will lapse

and become void.

Chief Executive Officer and primary insider in Ultimovacs ASA, Carlos de Sousa,

has been granted 9,500 share options. Following the grant, Carlos de Sousa and

closely related parties hold 21,556 shares and 425,535 options in the company.

For further information, please see www.ultimovacs.com

(http://www.ultimovacs.com) or contact:

Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA

Phone: +47 480 96 355

Carlos de Sousa, CEO

Phone: +47 908 92507

Anne Worsøe, Head of IR & Communication

Phone: +47 906 86815

AI assistant